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Although mitochondrial diseases have
diverse causes, they are all characterized
by defective oxidative phosphorylation.
Civiletto et al. show that overexpression
of the mitochondria-shaping protein
OPA1, which improves respiratory chain
efficiency, improves the phenotypes of
two pre-clinical models of defective
mitochondrial bioenergetics.
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Increased levels of themitochondria-shaping protein
Opa1 improve respiratory chain efficiency and pro-
tect from tissue damage, suggesting that it could
be an attractive target to counteract mitochondrial
dysfunction. Here we show that Opa1 overexpres-
sion ameliorates two mouse models of defective
mitochondrial bioenergetics. The offspring from
crosses of a constitutive knockout for the structural
complex I component Ndufs4 (Ndufs4/), and of a
muscle-specific conditional knockout for the com-
plex IV assembly factor Cox15 (Cox15sm/sm), with
Opa1 transgenic (Opa1tg) mice showed improved
motor skills and respiratory chain activities com-
pared to the naive, non-Opa1-overexpressing,
models. While the amelioration was modest in
Ndufs4/::Opa1tg mice, correction of cristae ultra-
structure and mitochondrial respiration, improve-
ment of motor performance and prolongation of
lifespan were remarkable in Cox15sm/sm::Opa1tg
mice. Mechanistically, respiratory chain supercom-
plexes were increased in Cox15sm/sm::Opa1tg mice,
and residual monomeric complex IV was stabilized.
In conclusion, cristae shape amelioration by con-
trolled Opa1 overexpression improves two mouse
models of mitochondrial disease.
INTRODUCTION
Mutations in mitochondrial DNA (mtDNA), and in the vast reper-
toire of nuclear genes that converge on the formation and func-
tion of the mitochondrial respiratory chain (MRC), are respon-
sible for primary ‘‘mitochondrial disorders,’’ a group of highly
heterogeneous conditions, hallmarked by faulty oxidative phos-
phorylation (OXPHOS), that can affect any organ, at any age, and
by anymode of transmission (Koopman et al., 2012).When taken
as a whole, mitochondrial disorders are among the most
frequent genetic diseases, affecting >1 in 5,000 individuals inCthe European population (Elliott et al., 2008). Despite substantial
progress in mitochondrial medicine, the complexity of mitochon-
drial biology and genetics still constitutes a major challenge for
understanding the mechanistic basis of mitochondrial disorders
and explains, at least in part, their huge clinical and biochemical
variability, which is also a major hurdle toward effective treat-
ment. However, the development of ‘‘general’’ therapeutic
strategies, extendable to diverse disease-associated OXPHOS
defects, is now a realistic goal, based on rapidly expanding
knowledge of the molecular mechanisms underpinning mito-
chondrial biogenesis, quality control, and signaling pathways.
Several of these mechanisms are related to the control of mito-
chondrial shape and organization of the mitochondrial network.
Mitochondria are highly dynamic organelles that fuse and
divide to adapt their structure and morphology to the energetic
needs of the cell (Kasahara and Scorrano, 2014). Dynamin-
related GTPases located on the inner and outer mitochondrial
membranes (IMMs and OMMs) control the fission and fusion
processes (Griparic and van der Bliek, 2001). Mitochondrial
fission and fusion regulate a number of cellular processes,
including organelle distribution during cell proliferation, bioener-
getics proficiency, mitochondrial calcium flux, mitochondrial
apoptosis, autophagy, and even complex morphogenetic pro-
cesses such as the formation of dendritic spines (Kasahara
and Scorrano, 2014). Fission is regulated by Dynamin-Related
Protein 1 (DRP1) and by its OMM partners Fission 1 (FIS1), Mito-
chondrial Fission Factor (MFF), and Mitochondrial Division (MID)
49 and 51; fusion is controlled by the OMM proteins Mitofusins 1
and 2 (MFN1 and 2) and by the IMM protein Optic Atrophy 1
(OPA1). In humans, eight OPA1 isoforms are produced by alter-
native splicing of a single gene (Delettre et al., 2001), which are
further processed by at least three proteases to form several
long (L) and short (S) forms of OPA1 (Anand et al., 2014; Ehses
et al., 2009; Griparic et al., 2007; Head et al., 2009; Ishihara
et al., 2006; Song et al., 2007), which oligomerize to form func-
tionally active quaternary structures (Frezza et al., 2006). In addi-
tion to its role in mitochondrial fusion, OPA1 controls the cristae
remodelling arm of mitochondrial apoptosis (Frezza et al., 2006)
and the physical and functional organization of the MRC com-
plexes in MRC supercomplexes (Cogliati et al., 2013). These
functional quaternary structures increase electron flow channel-
ling through MRC complexes during respiration, thus minimizingell Metabolism 21, 845–854, June 2, 2015 ª2015 The Authors 845
electron leaks (Acin-Perez and Enriquez, 2014; Enriquez and Le-
naz, 2014), and stabilize individual MRC complexes such as
Complex III, CIII (Acı´n-Pe´rez et al., 2004). Consequently, OPA1
levels directly affect mitochondrial respiratory efficiency (Cogliati
et al., 2013) and proteolytic inactivation of OPA1 has been shown
to occur in cells from mitochondrial disease patients (Duvezin-
Caubet et al., 2007). However, the role of OPA1 in vivo and the
potential of its stabilization as a strategy to combat mitochon-
drial dysfunction and disease remains unclear. Genetic ablation
of Opa1 is lethal during mouse embryonic development (Rahn
et al., 2013) and causes massive dysfunction also in postmitotic
tissues (L.S., unpublished data). On the other hand, high levels of
OPA1 overexpression are toxic in cells, leading to paradoxical
mitochondrial fragmentation (Cipolat et al., 2004). In order to
avoid these effects, we have used X-chromosome-targeted
Opa1 transgenesis (Opa1tg) to obtainmoderate, ubiquitous over-
expression in a mouse line (Cogliati et al., 2013). Remarkably,
Opa1tg mice are fertile and viable, have normal lifespan, and
are protected from a panoply of tissue insults, including denerva-
tion-induced skeletal muscle atrophy, brain and heart ischemia-
reperfusion damage, and liver failure caused by Fas-ligand-
induced apoptosis (see the accompanying paper by Varanita
et al., 2015). We therefore reasoned that Opa1 overexpression
could be exploited to correct the biochemical impairment and
mitigate the pathology associated with genetically determined
OXPHOS failure in available mouse models of mitochondrial
disease. To this aim, we crossed the Opa1tg mouse with (i) a
constitutive knockout mouse for Ndufs4 (Ndufs4–/–) (Karamanli-
dis et al., 2013; Kruse et al., 2008; Quintana et al., 2010; Quintana
et al., 2012), encoding the 18 kDa subunit of complex I (cI), and (ii)
a skeletal-muscle-specific knockout mouse for Cox15, in which
the Cre-recombinase-driven ablation of Cox15 is dependent
upon the muscle-specific actin gene promoter (Cox15sm/sm)
(Viscomi et al., 2011). Cox15 encodes a key enzyme in the
biosynthesis of heme a, an essential catalytic redox component
of complex IV ([CIV]; cytochrome c oxidase [COX]) (Bareth et al.,
2013; Barros et al., 2001; Barros and Tzagoloff, 2002; Glerum
et al., 1997; Petruzzella et al., 1998; Wang et al., 2009). In hu-
mans, mutations in NDUFS4 are associated with early-onset
fatal Leigh syndrome due to severe Complex I (CI) deficiency
(Petruzzella et al., 2001; Scacco et al., 2003; van den Heuvel
et al., 1998). Mutations in COX15 have been reported in children
with severe isolated cardiomyopathy, encephalopathy, or cardi-
oencephalomyopathy (Alfadhel et al., 2011; Antonicka et al.,
2003; Bugiani et al., 2005). Here we report that the mild Opa1
overexpression achieved in the Opa1tg mice corrects these





All procedures on animals were conducted under the UK Ani-
mals (Scientific Procedures) Act, 1986, and approved by the
local ethical review committee. To obtain transgenic overexpres-
sion of Opa1 in OXPHOS defective mouse lines, we crossed the
Opa1tg mouse with either Ndufs4–/– or Cox15sm/sm mice. The
constitutive Ndufs4–/– mouse shows severe CI deficiency, and846 Cell Metabolism 21, 845–854, June 2, 2015 ª2015 The Authorsthe accumulation of a catalytically inactive 830 kDa CI assembly
intermediate, associated with the onset of a rapidly progres-
sive syndrome, dominated by neurological impairment starting
approximately 40 days after birth (Calvaruso et al., 2012; Kruse
et al., 2008). The Cox15sm/sm mouse shows profound skeletal
muscle COX deficiency, leading to muscle wasting, severe mo-
tor performance impairment, and markedly reduced survival
(Viscomi et al., 2011).
Ndufs4–/–::Opa1tg Mice Live Longer and Show Better
Motor Coordination than Ndufs4–/– Mice
Western blot analysis on two animals for each genotype showed
tissue-specific increases in the levels of long and short forms of
OPA1 in brain (Figure S1A), skeletal muscle (Figure S1B), and
heart (Figure S1C) in Opa1tg and Ndufs4–/–::Opa1tg relative to
their Ndufs4–/– and wild-type (WT) littermates. Motor coordina-
tion, measured as latency to fall by weekly performed rotarod
test, showed steady downhill in both Ndufs4–/–::Opa1tg and
Ndufs4–/– groups, each composed of six animals. However, the
scores, which were identical in the two groups at the beginning
of the observation (week 4 after birth), showed significant differ-
ences in subsequent measurements, with the Ndufs4–/–::Opa1tg
group performing consistently better than the Ndufs4–/– group
in weeks 5 (latency to fall: 556 ± 39 versus 388 ± 46 s) and 6
(latency to fall: 384±56versus123±50s). Atweek7, bothgroups
were virtually unable to perform the test at any rate, due to
collapse of neurological conditions or death (Figure 1A). Further-
more, Kaplan-Meier analysis showed that survival probability
wasmoderately, but significantly, prolonged inNdufs4–/–::Opa1tg
versus Ndufs4–/– littermates (survival median: 62.0 versus
53.5 days; log-rank test p = 0.015) (Figure 1B). The amelioration
in motor coordination and prolongation of the lifespan was asso-
ciated with a1.5-fold increase in glutamate-malate-dependent
state-3 oxygen consumption rate of isolated brain mitochondria
(reflecting CI-driven respiration), which nevertheless remained
well below the values obtained in brain mitochondria of WT and
Opa1tg littermates (Figure 1C). Accordingly, CI activity,measured
by spectrophotometric assay (Figure 1D), was 2.5-fold in-
creased (p < 0.05) inNdufs4–/–::Opa1tg versusNdufs4–/– isolated
brain mitochondria. Several MRC complex subunits were
analyzed by western blotting on SDS-PAGE of isolated brain
mitochondria. Notably, the two tested CI subunits (NDUFA9
and NDUFB8), as well as the UQCRC2 subunit of CIII, were
increased 1.3-fold in Ndufs4–/–::Opa1tg versus Ndufs4–/– brain
mitochondria (Figure 1E). The p values of two-tail, unpaired Stu-
dent’s t test of densitometric analysis obtained from four inde-
pendent samples/genotype was p = 0.02 for NDUFA9, p = 0.04
for NDUFB8, and p = 0.01 for UQCRC2. Contrariwise, no signifi-
cant change was observed for SDHA (CII), COX1 (CIV), and
ATP5A (CV) subunits. Blue native gel electrophoresis (BNGE)-
based in-gel activity of CI and CI-containing supercomplexes
(sc) showed hardly any reactive band in both Ndufs4–/–::Opa1tg
double mutants and Ndufs4–/– littermates (Figure S1D). Western
blot analysis using antibodies against NDUFB8 (specific to CI),
UQCRC1 (specific to CIII), and COX1 (specific to CIV) showed,
in the same genotypes, a catalytically active 200 kDa assembly
intermediate as well as the catalytically inactive 830 kDa CI and
830 kDa+CIII2 assembly intermediates previously reported in
the Ndufs4–/– mouse model (Calvaruso et al., 2012), but neither
Figure 1. Improved Motor Function and
Extended Lifespan in Ndufs4–/–::Opa1tg
Double Mutants
(A) Rotarod analysis (n = 6/group). Dashed blue:
WT; dashed red: Opa1tg; solid blue: Ndufs4–/–;
solid red: Ndufs4–/–::Opa1tg. Error bars represent
SEM. The asterisks represent the significance
levels calculate by unpaired, two-tail Student’s
t test, *p < 0.05, ***p < 0.005, and refer to
the comparison between Ndufs4–/–::Opa1tg and
Ndufs4–/–.
(B) Kaplan-Meier survival probability. Significance
was assessed by the log rank test. Solid blue:
Ndufs4–/– (n = 16); solid red: Ndufs4–/–::Opa1tg
(n = 9).
(C) Oxygen consumption measurements (nmol
O2/min/mg of protein). Solid blue: WT (n = 5); blue
outline: Opa1tg (n = 5); solid red: Ndufs4–/– (n = 5);
red outline:Ndufs4–/–::Opa1tg (n = 6). The asterisks
represent the significance levels calculate by un-
paired, two-tail Student’s t test *p < 0.05.
(D) MRC activities (nmol/min/mg of protein) in
isolated brain mitochondria. Solid blue: WT (n = 8);
blue outline: Opa1tg (n = 5); solid red: Ndufs4–/–
(n = 7); red outline: Ndufs4–/–::Opa1tg (n = 8).
Error bars represent SEM. The asterisks represent
the significance levels calculate by unpaired, two-tail Student’s t test *p < 0.05.
(E) Western blot analysis of subunits from CI (NDUFA9 and NDUFB8), CII (SDHA), CIII (UQCRC2), CIV (COX1), and CV (ATP5A) in brain isolated mitochondria.
VDAC is taken as an internal control.
(F) Electron microscopy of brain specimens from the different genotypes. Note that mitochondrial morphology is well preserved in Ndufs4–/–::Opa1tg versus
Ndufs4–/–. Scale bar 1 mm.CI holocomplex nor CI supercomplexes containing CI+CIII2 or
CI+CIII2+CIV (Figure S1E). However, electron microscopy anal-
ysis of forebrain (Figure 1F) and cerebellum (not shown) sug-
gested amelioration in cristae architecture, with no change in
mitochondrial shape and dimensions.
These findings suggest that moderate Opa1 overexpression
partially rescues the phenotype of a CI-deficient mouse model
by improving cristae morphology.
Survival and Functional Improvement in the Double
Mutant Cox15sm/sm::Opa1tg Mice
Similar to Cox15sm/sm::Opa1tg, male and female Cox15sm/sm::
Opa1tg mice were smaller than WT or Opattg littermates (p <
0.005; n = 4 for each genotype; data not shown). To test muscle
performance, wemonthlymonitoredmotor endurance by a stan-
dard treadmill test starting at 2 months of age. Albeit still signif-
icantly lower than WT (n = 8) and Opa1tg (n = 9) littermates, the
scores of the Cox15sm/sm::Opa1tg double mutant group (n = 8)
were 2- to 3-fold higher than those of the Cox15sm/sm group
(n = 10) (p < 0.005 at each time point; Figure 2A). On average,
the distance covered by Cox15sm/sm::Opa1tg animals was three
times that of the Cox15sm/sm littermates (169 ± 20 versus 58 ±
6 m, p = 2.59 3 106) (Figure S2A). This improvement was re-
corded in both homozygous females and hemizygous males,
with no significant gender difference (Figure S2B). Interestingly,
Opa1Tg performed better than WT littermates (890 ± 50 versus
803 ± 27 m, p < 0.001; Figure S2A). We followed the animals
up to 6 months of age. Notably, Cox15sm/sm::Opa1tg double mu-
tants showed a remarkable increase in survival probability
compared to their Cox15sm/sm littermates (log-rank test p =
0.0003). Only 1/17 (7%) Cox15sm/sm::Opa1tg animal died duringCour observation period, versus 12/23 (50%) Cox15sm/sm litter-
mates (Figure 2B).
These findings indicate that controlled Opa1 overexpression
ameliorates life expectancy and motor function of a mouse
model of muscle CIV deficiency.
Amelioration of Mitochondrial Morphology and
Biochemistry in Cox15sm/sm::Opa1tg Muscle
H&E staining of the mid-portion of gastrocnemius muscle
(Figure 3A) showed numerous centralized nuclei in both
Cox15sm/sm and Cox15sm/sm::Opa1tg, the proportion of which
did not significantly differ between the two groups (Figure 3B).
However, the average cross-sectional area (CSA) of muscle
fibers was doubled in the Cox15sm/sm::Opa1tg relative to
Cox15sm/sm muscles (p < 0.05), although still smaller (50%)
than the areas measured in WT and Opa1tg muscles (p < 0.05)
(Figure 3C). We also tested whether the muscle hypotrophic
and dystrophic features of theCox15sm/smmice were associated
with increased apoptosis or altered autophagy. TUNEL staining
in muscle sections did not reveal hardly any positive fiber in
either Cox15sm/sm or Cox15sm/sm::Opa1tg, similar to WT and
Opa1Tg (not shown), suggesting that apoptosis is not a major
player in the pathogenesis of Cox15sm/sm myopathy. Immuno-
staining of muscle sections with Lamp1 and P62 antibodies
revealed increased reactions in Cox15sm/sm samples compared
to WT and Opa1Tg, which, however, did not change in
Cox15sm/sm::Opa1tg (not shown). These data indicate that
apoptosis and autophagy are unlikely to contribute to the
amelioration observed in Cox15sm/sm::Opa1tg mice.
Next, we performed ultrastructural analysis of muscle fibers
(Figure 4). Examination of tibialis anterior muscle revealedell Metabolism 21, 845–854, June 2, 2015 ª2015 The Authors 847
Figure 2. Improved Motor Function and Extended Lifespan in
Cox15sm/sm–::Opa1Tg Animals
(A) Treadmill analysis of motor performance. Dashed blue: WT (n = 8); dashed
red: Opa1tg (n = 9); solid blue: Cox15sm/sm (n = 10); solid red Cox15sm/sm::
Opa1tg (n = 8). Error bars represent SEM. The asterisks represent the signifi-
cance levels calculate by unpaired, two-tail Student’s t test, ***p < 0.005, and
refer to the comparison between Cox15sm/sm::Opa1tg and Cox15sm/sm.
(B) Kaplan–Meier survival probability. Significance was assessed by the
log rank test. Solid blue: Cox15sm/sm (n = 23); solid red: Cox15sm/sm::Opa1tg
(n = 17).marked improvement of mitochondrial and myofibrillary mor-
phology in Cox15sm/sm::Opa1tg compared to Cox15sm/sm. While
Cox15sm/sm muscle mitochondria showed profound cristae
disorganization and prominent vacuolar degeneration of the in-
ner mitochondrial compartment, the Cox15sm/sm::Opa1tg cristae
were organized in an ordered and parallel array and were tightly
folded, similar to those observed in WT and Opa1tg littermate
specimens (Figure 4A). No hyperfused organelles were observed
in Opa1Tg muscle. Likewise, myofibrils, which in Cox15sm/sm ap-
peared disorganized and separated from each other by the
accumulation of membranous and granular material, showed a
compact orderly array in Cox15sm/sm::Opa1tg, again resembling
those of WT and Opa1tg specimens (Figure 4A). Quantification
of area, perimeter, length, and width of muscle mitochondria
showed significantly increased values (1.5- to 5-fold) in
Cox15sm/sm, relative to WT and Opa1tg specimens, indicating
mitochondrial ballooning. These parameters were partially cor-
rected in Cox15sm/sm::Opa1tg samples (1.3- to 1.8-fold versus
WT) (Figure 4B).
We then tested whether the improvements in motor perfor-
mance andmuscle morphology observed inCox15sm/sm::Opa1tg
animals were associated with ameliorated biochemical parame-
ters. Glutamate-malate dependent state-3 oxygen consumption848 Cell Metabolism 21, 845–854, June 2, 2015 ª2015 The Authorsrate in isolatedmusclemitochondria (reflectingCI-driven respira-
tion) was decreased inCox15
sm/sm
animals (128 ± 37 nmol/min/mg
protein), but increased significantly in Cox15sm/sm::Opa1tg
(190 ± 48 nmol/min/mg; p < 0.05), up to lower normal values,
not significantly different from those obtained in WT (250 ±
84 nmol/min/mg) and Opa1Tg (276 ± 101 nmol/min/mg) samples
(Figure 5A). Similar results were obtained by measuring succi-
nate- and TMPD/ascorbate-dependent state-3 oxygen con-
sumption rate (reflecting CII- and CIV-driven respiration, respec-
tively) (Figure 5A). We also analyzed the activity of the single
respiratory complexes by spectrophotometric assays. The spe-
cific activity of CIV normalized to that of citrate synthase (CS)
was significantly increased (p < 0.05) in Cox15sm/sm::Opa1tg
(16 ± 3) versus Cox15sm/sm (10 ± 4) muscle homogenates, albeit
still much lower than that of WT (47 ± 18) orOpa1Tg (44 ± 7) mus-
cles (Figure 5B). These results were qualitatively confirmed by
histochemical COX staining, which showed reduced COX-nega-
tive fibers in COX/SDH double reaction in Cox15sm/sm::Opa1tg
versus Cox15sm/sm muscle fibers (Figure 5C).
Overall, these data indicate that the ameliorated Cox15sm/sm::
Opa1tg mitochondrial ultrastructure is accompanied by im-
proved respiration and CIV activity.
Mitochondrial Protein and Transcriptional Analysis in
Cox15sm/sm::Opa1tg Mice
In order to investigate the molecular bases of the observed
correction of mitochondrial respiration in Cox15sm/sm::Opa1tg
animals, we first analyzed the amount of subunits specific
to each MRC complex by western blotting analysis of muscle
homogenates separated by SDS-PAGE (Figure 6A). COX1, the
mtDNA-encoded largest CIV subunit, which contains the two
heme-a moieties and the CuB center, and COX4 (isoform 1), a
nucleus-encoded early-assembled CIV subunit, were both
reduced in Cox15sm/sm compared to WT and Opa1Tg samples,
but did increase in those from Cox15sm/sm::Opa1tg animals (Fig-
ure 6B). In both Cox15sm/sm and Cox15sm/sm::Opa1tg samples,
subunits of other MRC complexes were generally increased,
particularly the UQRCR2 subunit of CIII, suggesting compensa-
tory activation of MRC biogenesis induced by CIV deficiency.
Interestingly, analysis of mitochondrial and nuclear transcripts
of CIV subunits revealed a specific, marked reduction of mt-
Cox1 mRNA in Cox15sm/sm samples, which was fully rescued
in Cox15sm/sm::Opa1tg samples (Figure 6C). Conversely, other
mtDNA- (mt-Cox2) and nucleus-encoded (Cox4I1 and Cox5a)
transcripts were unchanged in Cox15sm/sm versus WT mice
and were not affected by Opa1 overexpression (Figure 6C).
We detected no quantitative change in any group of animals
for transcripts Ppargc1a and Tfam, encoding PGC-1a and
TFAM, respectively (Figure 6C). The mtDNA copy number,
which was increased in Cox15sm/sm, returned to WT levels in
Cox15sm/sm::Opa1tg (Figure S3A), suggesting normalization of
the homeostatic control on mtDNA maintenance (Scarpulla
et al., 2012). Importantly, the Cox15 transcript level measured
in skeletal muscle of Cox15sm/sm was 9% of that present in
WT and Opa1tg littermates and did not change significantly in
Cox15sm/sm::Opa1tg (Figure S3B), ruling out a direct effect of
Opa1 overexpression on Cox15 transcription.
In order to analyze the composition and amount of OPA1,
we performed a western blot experiment using an anti-OPA1
Figure 3. Improved Morphological Features
of Cox15sm/sm::Opa1Tg Skeletal Muscle
(A) H&E staining of skeletal muscles from mice of
the different genotypes. Scale bar 100 mm.
(B) Quantification of the number of centralized
nuclei in the different genotypes. 600 fibers/sam-
ple were analyzed (n = 4/genotype). Solid blue:
WT; blue outline: Opa1tg ; solid red: Cox15sm/sm;
red outline: Cox15sm/sm::Opa1tg. Statistical sig-
nificance was calculated by unpaired, two-tail
Student’s t test: ***p < 0.005. Error bars represent
SEM.
(C) Cross-sectional area of muscle fibers of
gastrocnemius. 600 fibers/sample were analyzed
(n = 4/genotype). Solid blue: WT; blue outline:
Opa1tg; solid red: Cox15sm/sm; red outline:
Cox15sm/sm::Opa1Tg. Statistical significance was
calculated by unpaired, two-tail Student’s t test:
*p < 0.05; **p < 0.01; ***p < 0.005. Error bars
represent SEM.antibody that specifically recognizes five OPA1 species in skel-
etal muscle, namely isoforms 1 and 7, and short forms 1–3, re-
sulting from proteolytic cleavage (Figure 6A). Densitometric
quantification showed a significant increase (1.4-fold) in the
amount of all five detected OPA1 species inOpa1tgmuscle sam-
ples relative to WT. The amount of OPA1 species was further
increased (1.3- to 1.8-fold) inCox15sm/sm versusWT and signif-
icantly more so in Cox15sm/sm::Opa1tg (1.5- to 2-fold), particu-
larly for the short forms 1–3 (Figure S3C).
These data suggest that Opa1 overexpression leads to stabi-
lization in CIV protein and transcript levels.
MRC Supercomplexes Are Increased in
Cox15sm/sm::Opa1tg Mice
Individual stability of MRC complexes depends on their assem-
bly in respiratory chain supercomplexes (sc) (Acı´n-Pe´rez et al.,
2004). We therefore analyzed CI and CIV BNGE in-gel
activities in digitonin-treated isolated muscle mitochondria. In
Cox15sm/sm samples, the intensity of the band corresponding
to individual CIV holocomplex wasmarkedly reduced, and hardly
any reaction was detected in the high-molecular-weight area
harboring sc. However, individual CIV in-gel activity was
increased, and CIV reactive high-molecular-weight bands were
clearly detected inCox15sm/sm::Opa1tgmitochondria (Figure 7A),
indicating stabilization of CIV holocomplex and CIV-containing
sc. Likewise, several high-molecular-weight CI-reactive bands,
corresponding to CI- and CIV-containing sc, were virtually ab-
sent in the same Cox15sm/sm samples but were clearly, albeit
weakly, visible in the Cox15sm/sm::Opa1tg samples (Figure 7B).
Western blot analysis on BNGE samples using an anti-COX1-
specific antibody confirmed the results of in-gel activity: a
band corresponding to CIV holocomplex was increased in
Cox15sm/sm::Opa1tg compared to Cox15sm/sm and high-molecu-
lar-weight Cox1-reactive bands, which were detected in WT andCell Metabolism 21, 845–Opa1Tg samples, were absent, even upon
long exposure, in Cox15sm/sm but clearly,
albeit weakly, visible in Cox15sm/sm::
Opa1tg samples (Figure 7C). Likewise, im-
munodetection of cI-containing sc withan anti-Ndufa9 antibody showed slight increased Ndufa9
amount in Cox15sm/sm::Opa1tg versus Cox15sm/sm (Figure 7D).
These results indicate that increased OPA1 levels stabilize
RCS and residual CIV in Cox15sm/sm mice.
DISCUSSION
The moderate overexpression of Opa1 achieved in the Opa1tg
mousemodel is well tolerated and compatible with normal devel-
opment, fertility, and lifespan. No obvious detrimental effects
were noted during the 6-month period of our experimental
observation; although, asmentioned in the accompanying paper
by Varanita et al. (2015), prolonged Opa1 overexpression may
lead to increased strain-specific prevalence of cancer, a some-
how expected result given the antiapoptotic role of OPA1. How-
ever, increased OPA1 amount in key tissues, including skeletal
and cardiac muscle, brain, and liver, confer remarkable protec-
tion against a wide spectrum of experimental tissue damage
models (accompanying paper by Varanita et al., 2015). Here,
we demonstrate that this effect can be exploited to improve
the motor performance, as well as biochemical and molecular
phenotypes of two mouse models of genetically determined
OXPHOS failure.
The Ndufs4–/– mouse is characterized by the complete
absence of a structural component of CI. In the current map of
mammalian CI, the NDUFS4 18 kDa subunit has been modeled
into a density in a cleft between the 75 kDa subunit and the
49 kDa, 30 kDa, and NDUFB8 (TYKY) subunits (Vinothkumar
et al., 2014). This localizationmay explain why diseasemutations
in the 18 kDa subunit lead to accumulation of late-stage interrup-
ted-assembly intermediates lacking the NADH-dehydrogenase
module (Calvaruso et al., 2012). The indispensable role of
NDUFS4 in preserving the CI structure and redox activity can
also explain the limited improvement in motor coordination,854, June 2, 2015 ª2015 The Authors 849
Figure 4. Amelioration of Mitochondrial Ul-
trastructure in Cox15sm/sm::Opa1Tg Skeletal
Muscle
(A) EM microphotographs of specimens from the
different genotypes. Note that while there is
accumulation of inter-myofibrillar amorphous ma-
terial and disorganization of the mitochondrial
cristae (inset) in the Cox15sm/sm, the myofibrillary
array and cristae structure (inset) are both well
preserved in the Cox15sm/sm::Opa1Tg. Mitochon-
dria appear larger and with denser cristae in
Opa1Tg than inWT. Scale bar 2 mm; scale bar of the
inset: 200 nm.
(B) Morphometric quantification of the area,
perimeter, length and width of mitochondria
from the different genotypes. A total of 200 mito-
chondria from WT and Opa1Tg mice (n = 2)
were analyzed, and 500 from Cox15sm/sm and
Cox15sm/sm::Opa1Tg (n = 2).measured by rotarod, and biochemical phenotypes observed
in Ndufs4–/–::Opa1tg double mutants. Rapamycin-induced inhi-
bition of mTOR, which was recently shown to alleviate the
phenotype, also failed to correct the CI defect of Ndufs4–/–
mice (Johnson et al., 2013). However, the cristae-centric
approach used here to treat CI deficiency improved survival to
levels comparable to those achieved by every-other-day rapa-
mycin administration (Johnson et al., 2013). It would be inter-
esting to verify if the combination of Opa1 overexpression and
mTOR inhibition is additive and can achieve even better amelio-
ration. We also cannot exclude that OPA1-driven correction
of OXPHOS failure may be less amenable in brain than in other
tissues, e.g., skeletal muscle.
The Cox15sm/sm mouse model is based on muscle-specific
ablation of Cox15, dependent on the activity of the Cre recombi-
nase under the control of the skeletal-muscle-specific actin
promoter. Although Cox15sm/sm animals display early-onset pro-
gressive mitochondrial myopathy, characterized by profound
muscle weakness andwasting leading to early death, the genetic
lesion underpinning this phenotype can be considered as a
hypomorphic mutant allele, the effects of which on COX activity
and MRC proficiency are severe but partial. Accordingly,
Cox15 transcript was drastically decreased, but not absent, in
Cox15sm/sm and Cox15sm/sm::Opa1tg muscles, explaining the
presence of some residual COX activity in muscle of adult ani-
mals and the ‘‘mosaic’’-like distribution of the histochemical re-
action to COX, which is preserved in scattered muscle fibers
(Figure 5C). The molecular Cox15sm/sm defect resembles that
of the majority of mitochondrial disorders (i.e., partial rather
than complete biochemical impairment) due to decreased but
not abolished function of the mutant gene product. Incidentally,
this category of mitochondrial diseases also includes the few
COX15 mutant patients reported in the literature (Alfadhel
et al., 2011; Antonicka et al., 2003; Bugiani et al., 2005). These
considerations may explain the marked and persistent improve-
ment of the motor performance observed in Cox15sm/sm::Opa1tg
double mutants and suggest that OXPHOS impairment due to
decreased, but not abolished, function of the mutant gene prod-
uct is amenable to correction by potentiating the effects of OPA1
on mitochondrial cristae shape and MRC function.850 Cell Metabolism 21, 845–854, June 2, 2015 ª2015 The AuthorsTheCox15sm/sm::Opa1tg animals displayed not only a dramatic
increase in motor endurance but also a remarkable extension of
survival up to, and in most cases well beyond, the 6-month
period of observation of our experimental protocol. These effects
were associated with robust increase of muscle mitochondrial
respiration accompanied by a milder but significant increase
of muscle COX activity. The discrepancy between the nearly
complete reversion to normal in the respiratory rate and the
modest increment of COX activity may be explained by
increased stabilization of CIV holocomplex and CIV-associated
supercomplexes, as indicated by results of BNGE in-gel activity
and immunoblotting. The recovery in the motor performance
and biochemical proficiency of the Cox15sm/sm::Opa1tg double
mutants was associated with marked correction of the profound
ultrastructural alteration in cristae morphology associated
with Cox15 ablation. This effect is likely to be directly connected
to the role of OPA1 in cristae shape and may be correlated
to partial stabilization of the CIV holocomplex and supercomplex
organization in the cristae membrane. Accordingly, both nu-
cleus- and mitochondria-encoded MRC subunits were in-
creased in Cox15sm/sm::Opa1tg versus Cox15sm/sm muscles,
while the corresponding transcripts were unchanged, with the
notable exception of mt-Cox1 mRNA. COX1 is the mtDNA-en-
coded catalytic CIV subunit that contains the heme-a moieties
essential for COX1 stabilization (Bareth et al., 2013). The concor-
dant decrease of both COX1 protein and mt-Cox1 mRNA in
Cox15sm/sm was completely reverted in Cox15sm/sm::Opa1tg.
Taken together, these results substantiate the possibility that in
mammals, as in Saccharomyces cerevisiae, COX1 biosynthesis
is regulated by a feedback mechanism linking translation and
post-translation processing to transcription (Herrmann et al.,
2013). In yeast, a key role in this homeostatic loop is carried
out by the mt-Cox1-specific translation activators MSS51 and
PET309 (Herrmann et al., 2013). The mammalian ortholog of
PET309 has been identified as the leucine-rich pentatricopeptide
repeat-containing (LRPPRC) protein, an RNA binding factor that
is mutated in French-Canadian, COX defective Leigh-like syn-
drome in humans (Mootha et al., 2003). Interestingly, LRPPRC
interacts with OPA1, at least in D. melanogaster (Banerjee and
Chinthapalli, 2014). However, as there is no obvious mammalian
Figure 5. Increased Respiration and Mrc
activities in Cox15sm/sm::Opa1Tg Skeletal
Muscle
(A) Oxygen consumption rate (nmol O2/min/mg of
protein). Solid blue:WT (n = 5); blue outline:Opa1tg
(n = 5); solid red: Cox15sm/sm (n = 5); red outline:
Cox15sm/sm::Opa1tg (n = 6). Error bars represent
SEM. The asterisks represent the significance
levels calculate by unpaired, two-tail Student’s
t test, *p < 0.05.
(B) MRC complex activities (nmol/min/mg of pro-
tein) in skeletal muscle mitochondria shown as a
percentage of CS activity. Solid blue: WT (n = 5);
blue outline: Opa1tg (n = 5); solid red: Cox15sm/sm
(n = 5); red outline: Cox15sm/sm::Opa1tg (n = 6).
Error bars represent SD. The asterisks represent
the significance levels calculate by unpaired, two-
tail Student’s t test, *p < 0.05.
(C) COX/SDH histochemical double staining.
Scale bar: 50 mm.ortholog of MSS51, and the 50 UTR sequence of the yeast Cox1
mRNA, to which MSS51 binds, is virtually absent in the mamma-
lian transcript, these feedback mechanisms are probably
different in their molecular details between yeast and mamma-
lian systems.
Finally, while apoptosis seems not to play a significant role in
Cox15sm/sm myopathy and is not increased in Cox15sm/sm::
Opa1tg samples, immunoanalysis suggested dysregulated auto-
phagy in response toCox15 ablation, but whether this is relevantCto the pathogenesis of the disease remains to be further
investigated.
Our study demonstrates that OPA1-dependent mitochondrial
cristae and sc stabilization is effective in correcting mitochon-
drial disease conditions characterized by partial, however se-
vere, MRC defects. OPA1 can even partially improve defects
caused by complete lack of mitochondrial CI via an unknown
mechanism. Our results indicate OPA1 as a new target for
effective therapy of primary mitochondrial disorders. From aFigure 6. Molecular Analysis of
Cox15sm/sm::Opa1tg Skeletal Muscle
(A) Western blot analysis of OPA1, SDHA (CII),
ATP5A (CV), UQCRC2 (CIII), NDUFA9 (CI), COX1,
and COX4 (CIV); GAPDH is taken as a loading
reference.
(B) Densitometric analysis of MRC subunits.
Solid blue: WT (n = 4); blue outline: Opa1tg
(n = 4); solid red: Cox15sm/sm (n = 4); red outline:
Cox15sm/sm::Opa1tg (n = 4). Error bars represent
SEM. The asterisks represent the significance
levels calculate by unpaired, two-tail Student’s
t test. **p < 0.01; ***p < 0.005.
(C) mRNA expression analysis of CIV- and
mitochondrial-biogenesis-related genes. Gene
transcripts, retrotranscribed into cDNA, were
quantified by RT-PCR; normalized to the amount
of the b-Actin gene transcript; taken as a standard;
and expressed as time-fold variation relative to the
WT. Error bars represent SEM. The asterisks
represent the significance levels calculate by
unpaired, two-tail Student’s t test. **p < 0.01;
***p < 0.005.
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Figure 7. Stabilization of Respiratory Complexes and Supercom-
plexes in Cox15sm/sm::Opa1Tg Skeletal Muscle
(A) CIV-specific BNGE in-gel activity. Note the increased staining of
the bands corresponding to CIV-holoenzyme and CIV-containing sc in
Cox15sm/sm::Opa1tg versus Cox15sm/sm.
(B) CI-specific BNGE in-gel activity. Note the increased staining of the bands
corresponding to the sc in Cox15sm/sm::Opa1tg versus Cox15sm/sm.
(C) Western blot analysis of MRC CIV from BNGE of digitonin-treated isolated
mitochondria. The blot was immunodecorated with an anti-COX1 antibody.
(D) Western blot analysis of MRC CI- and CIV-containing sc’s from BNGE of
digitonin-treated isolated mitochondria. The blot was immunodecorated with
an anti-NDUFB8 antibody.translational point of view, future work is warranted to elucidate
the molecular details underpinning these remarkable effects,
extend the experimental observation to additional OXPHOS-
defective models, and eventually transfer this set of proof-of-
principle observations into effective therapeutic approaches
by, for example, selecting compounds or bioreactors able to
control the expression or stability of OPA1 in suitablemammalian
cell systems and animal models.
EXPERIMENTAL PROCEDURES
Reagents and Materials
Antibodies (COX1, COX4, UQCRC2, NDUFA9, ATP5a, and SDHA) were from
Mitoscience, GAPDH were from Millipore, P62 was from Sigma, LC3-I/II was
from Cell Signaling, Lamp1 was from Sigma, and OPA1 was from BD
Biosciences.
Animal Work
All procedures were conducted under the UK Animals (Scientific Procedures)
Act, 1986, approved by Home Office license (PPL: 7538) and local ethical
review. The mice were kept on a C57Bl6/129Sv mixed background, and WT852 Cell Metabolism 21, 845–854, June 2, 2015 ª2015 The Authorslittermates were used as controls. The animals were maintained in a tempera-
ture- and humidity-controlled animal-care facility with a 12 hr light/dark cycle
and free access to water and food and were sacrificed by cervical dislocation.
Behavioral Analysis
A treadmill apparatus (Columbus Instruments) was used to measure motor ex-
ercise endurance according to the number of falls in the motivational grid dur-
ing a gradually accelerating program with speed initially at 6.5 m/min and
increasing by 0.5 m/min every 3 min. The test was terminated by exhaustion,
defined as >10 falls/min into the motivational grid.
A rotarod apparatus (UgoBasile) was used to assess coordination skills. After
two acclimation sessions, the mice underwent three trial sessions at least
20min apart, using a standard acceleration protocol pre-set by the constructor.
Oxygen Consumption Studies
Mouse brains were homogenized in 0.075M sucrose, 0.225Mmannitol, 1 mM
EGTA, and 0.01% fatty-acids-free BSA (pH 7.4); skeletal muscle were homog-
enized in 150 mM sucrose, 50 mM Tris-HCl, 50 mM KCl, 10 mM EDTA, 0.2%
BSA (pH 7.4), and subtilisin 1 mg/g of muscle (Frezza et al., 2007). Mitochon-
dria isolated by differential centrifugation and resuspended 25 mM sucrose,
75 mM sorbitol, 100 mM KCl, 0.05 mM EDTA, 5 mM MgCl2, 10 mM Tris-HCl
(pH7.4), and 10 mM H3PO4 (pH 7.4) (Ferna´ndez-Vizarra et al., 2002).
For oxygraphic measurements, 250–500 mg of mitochondrial proteins were
incubated in a buffer containing 225 mM sucrose, 75 mM mannitol, 10 mM
Tris-HCl (pH 7.4), 10 mM KCl, 10 mM KH2PO4, 5 mM MgCl2, and 1 mg/ml
fatty-acids-free BSA (pH 7.4). Oxygen consumption was evaluated by a Clark
oxygen electrode (Hansatech, Instruments), using the following substrates and
inhibitors concentrations: 5 mM glutamate and 2.5 mM malate for cI-depen-
dent respiration, 5 mM succinate and 2 mM rotenone for cII-dependent
respiration, 6 mM ascorbate, and 300 mM TMPD and antimycin A 0.25 mg/ml
for cIV-dependent respiration. 100 mM ADP was added to stimulate ATP-
coupled oxygen consumption. 100 mMNaCN was added to completely inhibit
respiration (Frezza et al., 2007).
BNGE
For BNGE analysis, 250 mg of mitochondria isolated as described above
were resuspended in native page buffer (Invitrogen), protease inhibitors, and
4% digitonin and incubated for 1 hr on ice before centrifuging at 20,0003 g at
4C. 5%CoomassieG250was added to the supernatant. 30 mgwere separated
by 3%–12% gradient BNGE and either stained with for in-gel activities or elec-
troblotted on PVDF membranes for immunodetection (Nijtmans et al., 2002).
Morphological Analysis
For histochemical analysis, tissues were frozen in liquid-nitrogen-pre-cooled
isopentane. 8-mm-thick sections were stained for COX and SDH, as described
Sciacco and Bonilla (1996). Analysis of centralized nuclei and analysis was
performed on H&E-stained sections using ImageJ on four samples/genotype
(600 fibers/sample). For ultrastructural studies, samples were fixed with
2.5% glutaraldehyde in 10 mM phosphate buffer (pH 7.4). Quantification of
mitochondrial morphometry (area, perimeter, long axis, and short axis) in
electron micrographs was performed using ImageJ on 200 mitochondria
from WT and Opa1tg muscles and 500 mitochondria from Cox15sm/sm and
Cox15sm/sm::Opa1tg muscles.
Biochemical Analysis of MRC Complexes
Brain and skeletal muscle samples were snap-frozen in liquid nitrogen and
homogenized in 10 mM phosphate buffer (pH 7.4). The spectrophotometric
activity of CI, CII, CIII, and CIV, as well as CS, was measured as described
in Bugiani et al. (2004).
Real-Time PCR
MtDNA content and transcripts analysis was carried out by SYBR Green real-
time PCR, as described in Viscomi et al. (2011).
Western Blot Analysis
Mouse tissues were homogenized in ten volumes of 10 mM potassium phos-
phate buffer (pH 7.4). Mitochondrial-enriched fractions were collected after
centrifugation at 800 3 g for 10 min in the presence of protease inhibitors,
and frozen and thawed three times in liquid nitrogen. Protein concentration
was determined by the Lowry method. Aliquots, 70 mg each, were run through
a 4%–12% SDS-PAGE and electroblotted onto a nitrocellulose membrane,
which was then immunodecorated with different antibodies.
Statistical Analysis
All numerical data are expressed as mean ± SEM. Student’s unpaired two-tail
t test and Kaplan-Meier distribution were used for statistical analysis. Differ-
ences were considered statistically significant for p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at http://dx.doi.org/10.1016/j.cmet.2015.04.016.
AUTHOR CONTRIBUTIONS
G.C. carried out the in vivo phenotype analysis and performed biochemical
measurements and molecular analysis and wrote the manuscript; T.V. gener-
ated mouse colonies, carried out BNGE in-gel activity, western blot, and ultra-
structural analysis and wrote the manuscript; T.G. and S.B. helped to carry out
in vivo phenotype analysis; R.C., S.M., and C.L. carried out histological, histo-
chemical, and morphometric analysis; C.V. supervised and participated in the
experimental design, supervised the experimental work, and contributed to
write the manuscript; L.S. and M.Z. designed the study and wrote the
manuscript.
ACKNOWLEDGMENTS
This work was supported by: Telethon-Italy GPP10005 (to M.Z. and L.S.),
GGP11011 (to M.Z.), GGP12162, GGP14187A (to L.S.), AIRC IG 11716-2011
(to L.S.), Cariplo 2011-0526 (to M.Z.), ERC FP7-322424 (to M.Z.) and FP7-
282280 (to L.S.), FP7 CIG PCIG13-GA-2013-618697 (to L.S.), Italian Ministry
of Research FIRB RBAP11Z3YA_005 (to L.S.), and Italian Ministry of Health
GR-2010-2306-756 (to C.V.). We are grateful to the personnel at Phenomics
and ARES animal care facilities for skillful technical assistance.
Received: September 29, 2014
Revised: February 13, 2015
Accepted: April 12, 2015
Published: June 2, 2015
REFERENCES
Acin-Perez, R., and Enriquez, J.A. (2014). The function of the respiratory super-
complexes: the plasticity model. Biochim. Biophys. Acta 1837, 444–450.
Acı´n-Pe´rez, R., Bayona-Bafaluy, M.P., Ferna´ndez-Silva, P., Moreno-
Loshuertos, R., Pe´rez-Martos, A., Bruno, C., Moraes, C.T., and Enrı´quez,
J.A. (2004). Respiratory complex III is required to maintain complex I in
mammalian mitochondria. Mol. Cell 13, 805–815.
Alfadhel, M., Lillquist, Y.P., Waters, P.J., Sinclair, G., Struys, E., McFadden, D.,
Hendson, G., Hyams, L., Shoffner, J., and Vallance, H.D. (2011). Infantile car-
dioencephalopathy due to a COX15 gene defect: report and review. Am. J.
Med. Genet. A. 155A, 840–844.
Anand, R., Wai, T., Baker, M.J., Kladt, N., Schauss, A.C., Rugarli, E., and
Langer, T. (2014). The i-AAA protease YME1L and OMA1 cleave OPA1 to bal-
ance mitochondrial fusion and fission. J. Cell Biol. 204, 919–929.
Antonicka, H., Mattman, A., Carlson, C.G., Glerum, D.M., Hoffbuhr, K.C.,
Leary, S.C., Kennaway, N.G., and Shoubridge, E.A. (2003). Mutations in
COX15 produce a defect in the mitochondrial heme biosynthetic pathway,
causing early-onset fatal hypertrophic cardiomyopathy. Am. J. Hum. Genet.
72, 101–114.
Banerjee, S., and Chinthapalli, B. (2014). A proteomic screen with Drosophila
Opa1-like identifies Hsc70-5/Mortalin as a regulator of mitochondrial
morphology and cellular homeostasis. Int. J. Biochem. Cell Biol. 54, 36–48.CBareth, B., Dennerlein, S., Mick, D.U., Nikolov, M., Urlaub, H., and Rehling, P.
(2013). The heme a synthase Cox15 associates with cytochrome c oxidase as-
sembly intermediates during Cox1 maturation. Mol. Cell. Biol. 33, 4128–4137.
Barros, M.H., and Tzagoloff, A. (2002). Regulation of the heme A biosynthetic
pathway in Saccharomyces cerevisiae. FEBS Lett. 516, 119–123.
Barros, M.H., Carlson, C.G., Glerum, D.M., and Tzagoloff, A. (2001).
Involvement of mitochondrial ferredoxin and Cox15p in hydroxylation of
heme O. FEBS Lett. 492, 133–138.
Bugiani, M., Invernizzi, F., Alberio, S., Briem, E., Lamantea, E., Carrara, F.,
Moroni, I., Farina, L., Spada, M., Donati, M.A., et al. (2004). Clinical and molec-
ular findings in children with complex I deficiency. Biochim. Biophys. Acta
1659, 136–147.
Bugiani, M., Tiranti, V., Farina, L., Uziel, G., and Zeviani, M. (2005). Novel mu-
tations in COX15 in a long surviving Leigh syndrome patient with cytochrome c
oxidase deficiency. J. Med. Genet. 42, e28.
Calvaruso, M.A., Willems, P., van den Brand, M., Valsecchi, F., Kruse, S.,
Palmiter, R., Smeitink, J., and Nijtmans, L. (2012). Mitochondrial complex III
stabilizes complex I in the absence of NDUFS4 to provide partial activity.
Hum. Mol. Genet. 21, 115–120.
Cipolat, S., Martins de Brito, O., Dal Zilio, B., and Scorrano, L. (2004). OPA1
requires mitofusin 1 to promote mitochondrial fusion. Proc. Natl. Acad. Sci.
USA 101, 15927–15932.
Cogliati, S., Frezza, C., Soriano, M.E., Varanita, T., Quintana-Cabrera, R.,
Corrado, M., Cipolat, S., Costa, V., Casarin, A., Gomes, L.C., et al. (2013).
Mitochondrial cristae shape determines respiratory chain supercomplexes as-
sembly and respiratory efficiency. Cell 155, 160–171.
Delettre, C., Griffoin, J.M., Kaplan, J., Dollfus, H., Lorenz, B., Faivre, L.,
Lenaers, G., Belenguer, P., and Hamel, C.P. (2001). Mutation spectrum and
splicing variants in the OPA1 gene. Hum. Genet. 109, 584–591.
Duvezin-Caubet, S., Koppen, M., Wagener, J., Zick, M., Israel, L., Bernacchia,
A., Jagasia, R., Rugarli, E.I., Imhof, A., Neupert, W., et al. (2007). OPA1 pro-
cessing reconstituted in yeast depends on the subunit composition of the
m-AAA protease in mitochondria. Mol. Biol. Cell 18, 3582–3590.
Ehses, S., Raschke, I., Mancuso, G., Bernacchia, A., Geimer, S., Tondera, D.,
Martinou, J.C., Westermann, B., Rugarli, E.I., and Langer, T. (2009). Regulation
of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes
and OMA1. J. Cell Biol. 187, 1023–1036.
Elliott, H.R., Samuels, D.C., Eden, J.A., Relton, C.L., and Chinnery, P.F. (2008).
Pathogenic mitochondrial DNA mutations are common in the general popula-
tion. Am. J. Hum. Genet. 83, 254–260.
Enriquez, J.A., and Lenaz, G. (2014). Coenzyme q and the respiratory chain:
coenzyme q pool and mitochondrial supercomplexes. Mol. Syndromol. 5,
119–140.
Ferna´ndez-Vizarra, E., Lo´pez-Pe´rez, M.J., and Enriquez, J.A. (2002). Isolation
of biogenetically competent mitochondria from mammalian tissues and
cultured cells. Methods 26, 292–297.
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G.V.,
Rudka, T., Bartoli, D., Polishuck, R.S., Danial, N.N., De Strooper, B., and
Scorrano, L. (2006). OPA1 controls apoptotic cristae remodeling indepen-
dently from mitochondrial fusion. Cell 126, 177–189.
Frezza, C., Cipolat, S., and Scorrano, L. (2007). Organelle isolation: functional
mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc.
2, 287–295.
Glerum, D.M., Muroff, I., Jin, C., and Tzagoloff, A. (1997). COX15 codes for a
mitochondrial protein essential for the assembly of yeast cytochrome oxidase.
J. Biol. Chem. 272, 19088–19094.
Griparic, L., and van der Bliek, A.M. (2001). The many shapes of mitochondrial
membranes. Traffic 2, 235–244.
Griparic, L., Kanazawa, T., and van der Bliek, A.M. (2007). Regulation of the
mitochondrial dynamin-like protein Opa1 by proteolytic cleavage. J. Cell
Biol. 178, 757–764.
Head, B., Griparic, L., Amiri, M., Gandre-Babbe, S., and van der Bliek, A.M.
(2009). Inducible proteolytic inactivation of OPA1 mediated by the OMA1 pro-
tease in mammalian cells. J. Cell Biol. 187, 959–966.ell Metabolism 21, 845–854, June 2, 2015 ª2015 The Authors 853
Herrmann, J.M., Woellhaf, M.W., and Bonnefoy, N. (2013). Control of protein
synthesis in yeast mitochondria: the concept of translational activators.
Biochim. Biophys. Acta 1833, 286–294.
Ishihara, N., Fujita, Y., Oka, T., and Mihara, K. (2006). Regulation of mitochon-
drial morphology through proteolytic cleavage of OPA1. EMBO J. 25, 2966–
2977.
Johnson, S.C., Yanos, M.E., Kayser, E.B., Quintana, A., Sangesland, M.,
Castanza, A., Uhde, L., Hui, J., Wall, V.Z., Gagnidze, A., et al. (2013). mTOR in-
hibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.
Science 342, 1524–1528.
Karamanlidis, G., Lee, C.F., Garcia-Menendez, L., Kolwicz, S.C., Jr.,
Suthammarak, W., Gong, G., Sedensky, M.M., Morgan, P.G., Wang, W., and
Tian, R. (2013). Mitochondrial complex I deficiency increases protein acetyla-
tion and accelerates heart failure. Cell Metab. 18, 239–250.
Kasahara, A., and Scorrano, L. (2014). Mitochondria: from cell death execu-
tioners to regulators of cell differentiation. Trends Cell Biol. 24, 761–770.
Koopman, W.J., Willems, P.H., and Smeitink, J.A. (2012). Monogenic mito-
chondrial disorders. N. Engl. J. Med. 366, 1132–1141.
Kruse, S.E., Watt, W.C., Marcinek, D.J., Kapur, R.P., Schenkman, K.A., and
Palmiter, R.D. (2008). Mice with mitochondrial complex I deficiency develop
a fatal encephalomyopathy. Cell Metab. 7, 312–320.
Mootha, V.K., Lepage, P., Miller, K., Bunkenborg, J., Reich, M., Hjerrild, M.,
Delmonte, T., Villeneuve, A., Sladek, R., Xu, F., et al. (2003). Identification of
a gene causing human cytochrome c oxidase deficiency by integrative geno-
mics. Proc. Natl. Acad. Sci. USA 100, 605–610.
Nijtmans, L.G., Henderson, N.S., and Holt, I.J. (2002). Blue Native electropho-
resis to study mitochondrial and other protein complexes. Methods 26,
327–334.
Petruzzella, V., Tiranti, V., Fernandez, P., Ianna, P., Carrozzo, R., and Zeviani,
M. (1998). Identification and characterization of human cDNAs specific to
BCS1, PET112, SCO1, COX15, and COX11, five genes involved in the forma-
tion and function of the mitochondrial respiratory chain. Genomics 54,
494–504.
Petruzzella, V., Vergari, R., Puzziferri, I., Boffoli, D., Lamantea, E., Zeviani, M.,
and Papa, S. (2001). A nonsense mutation in the NDUFS4 gene encoding the
18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the
complex in a patient with Leigh-like syndrome. Hum. Mol. Genet. 10, 529–535.854 Cell Metabolism 21, 845–854, June 2, 2015 ª2015 The AuthorsQuintana, A., Kruse, S.E., Kapur, R.P., Sanz, E., and Palmiter, R.D. (2010).
Complex I deficiency due to loss of Ndufs4 in the brain results in progressive
encephalopathy resembling Leigh syndrome. Proc. Natl. Acad. Sci. USA 107,
10996–11001.
Quintana, A., Morgan, P.G., Kruse, S.E., Palmiter, R.D., and Sedensky, M.M.
(2012). Altered anesthetic sensitivity of mice lacking Ndufs4, a subunit of mito-
chondrial complex I. PLoS ONE 7, e42904.
Rahn, J.J., Stackley, K.D., and Chan, S.S. (2013). Opa1 is required for proper
mitochondrial metabolism in early development. PLoS ONE 8, e59218.
Scacco, S., Petruzzella, V., Budde, S., Vergari, R., Tamborra, R., Panelli, D.,
van den Heuvel, L.P., Smeitink, J.A., and Papa, S. (2003). Pathological muta-
tions of the human NDUFS4 gene of the 18-kDa (AQDQ) subunit of complex I
affect the expression of the protein and the assembly and function of the com-
plex. J. Biol. Chem. 278, 44161–44167.
Scarpulla, R.C., Vega, R.B., and Kelly, D.P. (2012). Transcriptional integration
of mitochondrial biogenesis. Trends Endocrinol. Metab. 23, 459–466.
Sciacco, M., and Bonilla, E. (1996). Cytochemistry and immunocytochemistry
of mitochondria in tissue sections. Methods Enzymol. 264, 509–521.
Song, Z., Chen, H., Fiket, M., Alexander, C., and Chan, D.C. (2007). OPA1 pro-
cessing controls mitochondrial fusion and is regulated by mRNA splicing,
membrane potential, and Yme1L. J. Cell Biol. 178, 749–755.
Varanita, T., Soriano, M.E., Romanello, V., Zaglia, T., Quintana-Cabrera, R.,
et al. (2015). The Opa1-dependent mitochondrial cristae remodeling pathway
controls atrophic, apoptotic and ischemic tissue damage. Cell Met. 21, this
issue, 834–844.
van den Heuvel, L., Ruitenbeek, W., Smeets, R., Gelman-Kohan, Z., Elpeleg,
O., Loeffen, J., Trijbels, F., Mariman, E., de Bruijn, D., and Smeitink, J.
(1998). Demonstration of a new pathogenic mutation in human complex I defi-
ciency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ)
subunit. Am. J. Hum. Genet. 62, 262–268.
Vinothkumar, K.R., Zhu, J., and Hirst, J. (2014). Architecture of mammalian
respiratory complex I. Nature 515, 80–84.
Viscomi, C., Bottani, E., Civiletto, G., Cerutti, R., Moggio, M., Fagiolari, G.,
Schon, E.A., Lamperti, C., and Zeviani, M. (2011). In vivo correction of COX
deficiency by activation of the AMPK/PGC-1a axis. Cell Metab. 14, 80–90.
Wang, Z., Wang, Y., and Hegg, E.L. (2009). Regulation of the heme A biosyn-
thetic pathway: differential regulation of heme A synthase and heme O syn-
thase in Saccharomyces cerevisiae. J. Biol. Chem. 284, 839–847.
